Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963650 | 1.00 | FPR2 (0.37) | FPR2PROKR1MAPTNR2F2HTT | |
| SCHEMBL961684 | 0.90 | MAPT (0.38) | MAPTNR2F2HTTSMN1; SMN2 | |
| SCHEMBL961685 | 0.90 | MAPT (0.38) | MAPTNR2F2HTTSMN1; SMN2 | |
| SCHEMBL964044 | 0.90 | ATM (0.36) | FPR2PROKR1MAPTNR2F2HTT | |
| SCHEMBL964047 | 0.90 | ATM (0.36) | FPR2PROKR1MAPTNR2F2HTT | |
| SCHEMBL965070 | 0.89 | HTT (0.36) | FPR2PROKR1MAPTNR2F2HTT | |
| SCHEMBL965067 | 0.89 | HTT (0.36) | FPR2PROKR1MAPTNR2F2HTT | |
| SCHEMBL965616 | 0.89 | MAPT (0.36) | MAPTNR2F2HTTSMN1; SMN2LMNA | |
| SCHEMBL965612 | 0.89 | MAPT (0.36) | MAPTNR2F2HTTSMN1; SMN2LMNA | |
| SCHEMBL966295 | 0.88 | HTT (0.36) | FPR2PROKR1MAPTNR2F2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | FPR2 3820/4885PROKR1 2037/4885MAPT 4343/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | FPR2 1722/4885PROKR1 455/4885MAPT 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.